Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pleural Effusion, Malignant × rilotumumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pleural Effusion, Malignant 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Gastrointestinal Neoplasms 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

talimogene laherparepvec 1 rilotumumab 1 ganitumab 1 camrelizumab 1 Thiostrepton 1 Silver Nitrate 1 Nivolumab 1 Etoposide 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00791154 2024-08-23

SCLC

NantCell, Inc.

Phase 1/2 Terminated

213 enrolled 16 charts

Lung Neoplasms, Pleural Effusion, Malignant, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡